Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics

NCT02360319 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

489

Enrollment

OTHER

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Any FDA approved antipsychotic agent
DRUG: aripiprazole long acting injectable formulation

Sponsor

Vanguard Research Group

Collaborators

[object Object]